The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | An introduction into the PATHEMA trial
Bruno Paiva, PhD of the University of Navarra, Pamplona, Spain, talks about the results of the PATHEMA trial, a phase 3 clinical trial for newly diagnosed transplant-eligible multiple myeloma (MM) patients, presented at ASH 2017.
Paiva explains that there were two abstracts presented at ASH 2017 which spoke about this clinical trial. One focused on the efficacy of induction therapy and the toxicity. The other focused on the impact in terms of patient outcomes about MRD assessment, using next generation flow for the first time in a perspective fashion.
Recorded at the American Society of Hematology Annual Meeting 2017, held in Atlanta, GA.
